Skip to content Skip to footer
Subscribe Now
NEWS

Profluent Signs ~$2.25B Pact with Eli Lilly to Advance AI-Designed Recombinases for Genetic Medicines

Shots: Profluent has entered into a multi-program strategic research collaboration with Eli Lilly to develop & commercialize custom site-specific recombinases to address diseases with unmet needs As per the deal, Profluent will use its AI models to design & optimize site-specific recombinases for multiple genomic targets, while Lilly will gain exclusive rights to selected assets…
3 days ago

Read more

NEWS

Eli Lilly to Acquire Kelonia Therapeutics for ~$7B

Shots: Eli Lilly has entered into a definitive agreement to acquire Kelonia Therapeutics, expanding Lilly’s genetic medicine capabilities As per the deal, Lilly will acquire Kelonia for ~$7B in cash, incl. $3.25B upfront, & additional clinical, regulatory & commercial milestone payments; closing expected in H2’26 Acquisition will add Kelonia’s in vivo gene placement system (iGPS0) & its lead asset, KLN-1010, a one-time IV…
April 21, 2026

Read more

NEWS

Eli Lilly to Acquire Orna Therapeutics for ~$2.4B

Shots: Eli Lilly has entered into a definitive agreement to acquire Orna Therapeutics, gaining a broad platform to drive long-term innovation in genetic medicine & in vivo cell engineering As per the deal, Lilly will acquire Orna, with Orna’s shareholders receiving up to $2.4B in cash, incl. an upfront & subsequent clinical development milestones payment Acquisition…
February 10, 2026

Read more

CXO TALKS

CXO Talks: Thomas Chalberg & Annahita Keravala from Genascence in a Candid Conversation with PharmaShots

Shots: PharmaShots speaks with Thomas Chalberg, Founder and CEO of Genascence Corporation, and Annahita Keravala, Founder and CSO of Genascence Corporation Thomas and Annahita speak eloquently about Genascence's current lead program, GNSC-001, for osteoarthritis of the knee, and shed light on the unmet medical needs in the disease The duo highlighted the safety and tolerability…
August 11, 2025

Read more

Viewpoints_Dietrich Stephan
VIEWPOINTS

PharmaShots Interview: NeuBase Therapeutics’ Dietrich Stephan Shares Insight on its Approach to Genetic Medicine

In an interview with PharmaShots, Dietrich Stephan, Ph.D., CEO of NeuBase Therapeutics shared his views on the importance of preclinical in vivo data for PATrOL-enabled anti-gene for myotonic dystrophy type 1. Shots: NeuBase announced in vitro and in vivo data for its DM1 program, demonstrating the potential of its genetic medicine platform to target the disease-causing…
April 6, 2021

Read more